In particular, after treatment with AR pathway inhibitors, such as enzalutamide and abiraterone, PCa cells can undergo transdifferentiation, leading to the emergence of neuroendocrine PCa (NEPC), which is characterized by AR signaling independence and low expression of AR, PSA, and PSMA. The gene discussed is PROS1; the disease is posterior cortical atrophy.